{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:39:07Z","timestamp":1770889147602,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jid.2021.11.012","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T23:52:57Z","timestamp":1639698777000},"page":"275-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermolysis Bullosa Simplex"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2133-4256","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Ragot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-7512","authenticated-orcid":false,"given":"Alain","family":"Hovnanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.11.012_bib1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdermsci.2015.01.001","article-title":"Gene expression profiling in pachyonychia congenita skin","volume":"77","author":"Cao","year":"2015","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jid.2021.11.012_bib2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jid.2016.03.001","article-title":"Identification of alpha-adrenergic agonists as potential therapeutic agents for dermatomyositis through drug-repurposing using public expression datasets","volume":"136","author":"Cho","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.012_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2009.07.008","article-title":"Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients","volume":"56","author":"Hickerson","year":"2009","journal-title":"J\u00a0Dermatol Sci"},{"issue":"Suppl. 220","key":"10.1016\/j.jid.2021.11.012_bib4","first-page":"7","article-title":"Losartan for RDEB trial: results and international perspectives","volume":"100","author":"Kiritsi","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2021.11.012_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jid.2021.11.012_bib6","article-title":"Transcriptomic repositioning analysis identifies mTOR inhibitor as pential therapy for epidermolysis bullosa simplex [e-pub ahead of print]","author":"Lee","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.012_bib7","doi-asserted-by":"crossref","first-page":"e97071","DOI":"10.1172\/jci.insight.97071","article-title":"Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment","volume":"2","author":"Mirza","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2021.11.012_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2021.11.012_bib9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","article-title":"Diacerein orphan drug development for epidermolysis bullosa simplex: a phase 2\/3 randomized, placebo-controlled, double-blind clinical trial","volume":"78","author":"Wally","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.11.012_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamadermatol.2019.4141","article-title":"Targeted inhibition of the epidermal growth factor receptor and mammalian target of rapamycin signaling pathways in Olmsted syndrome","volume":"156","author":"Zhang","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21025215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21025215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:25:55Z","timestamp":1758302755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21025215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0022202X21025215"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.012","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermolysis Bullosa Simplex","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.07.170","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}